8-K: TOMI Environmental Solutions Reports Mixed Q1 2024 Results Amidst Pipeline Growth

TOMI Environmental Solutions reported a decrease in revenue for the first quarter of 2024, but saw growth in its sales pipeline and increased demand for its CES systems and iHP corporate service.

Summary

• TOMI Environmental Solutions announced its financial results for the first quarter of 2024, showing a decrease in total net revenue to $1.114 million compared to $1.582 million in the same period last year.
• The company's gross margin slightly increased to 60.2% from 59.5%.
• Operating loss was ($1.226 million), compared to ($1.188 million) in the first quarter of 2023.
• Net loss for the quarter was ($1.310 million), or ($0.07) per share, compared to ($1.187 million), or ($0.06) per share, in the prior year.
• Despite the revenue decrease, TOMI's sales backlog at the end of the quarter was $900,000, expected to be recognized in the second and third quarters of 2024.
• The company experienced a 21% quarter-over-quarter growth in its SteraMist iHP service revenue, reaching $371,000.
• TOMI also secured a contract for a $600,000 CES installation with a life sciences company, expected to be completed by the end of the third quarter of 2024.
• The Department of Homeland Security has allocated approximately $2,000,000 for 16 SteraMist Environment Systems to support decontamination at the Plum Island Animal Disease Center.
• TOMI submitted a proposal to the Department of Defense for a $3,000,000 grant related to ethylene oxide mitigation.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to decreased revenue and increased losses, but there are positive signs in pipeline growth and new contracts. The company needs to improve its financial performance to justify a higher sentiment score.

Positives

• The company experienced a 21% quarter-over-quarter growth in its SteraMist iHP service revenue.
• TOMI secured a new contract for a $600,000 CES installation.
• The Department of Homeland Security allocated approximately $2,000,000 for SteraMist systems.
• The company has a sales backlog of $900,000 expected to be recognized in the next two quarters.
• Two CES systems delivered in 2022 have been qualified for use, potentially generating $250,000 in annual BIT solution revenue.
• TOMI received the Gold Safety Award from Highwire.

Negatives

• Total net revenue decreased to $1.114 million from $1.582 million year-over-year.
• The company reported an operating loss of ($1.226 million), which is slightly worse than the ($1.188 million) loss in the same quarter last year.
• Net loss increased to ($1.310 million) from ($1.187 million) year-over-year.
• Cash and cash equivalents decreased to approximately $1.1 million from $2.3 million at the end of 2023.

Risks

• The company's ability to acquire new customers and expand sales is a risk.
• Reliance on a single or a few products for a majority of revenues poses a risk.
• General business and economic conditions could impact the company's performance.
• The company's ability to manage growth and generate sales is a risk.
• The company's ability to maintain and manage growth and generate sales is a risk.

Future Outlook

The company expects its $900,000 sales backlog to be recognized primarily in the second and third quarters of 2024 and anticipates continued growth in its sales pipeline and market demand, particularly in the pharmaceuticals and healthcare sectors. TOMI also expects to see revenue from the two qualified CES systems and the new $600,000 CES installation.

Management Comments

• Although revenue was below expectation in the first quarter, we saw continued growth in our sales pipeline, as well as an increase in demand for our CES systems and iHP corporate service.
• Were seeing positive signs throughout the marketplace, particularly in the pharmaceuticals and healthcare sectors, where were seeing increased pipeline activity.
• We are off to a solid start in 2024 and will continue to focus on executing our strategies to grow revenues, expand business development and deliver improved results and value for our shareholders.

Industry Context

The announcement reflects the ongoing demand for disinfection and decontamination solutions, particularly in the healthcare and pharmaceutical sectors. The inclusion of SteraMist technology in the Department of Homeland Security's budget highlights the growing recognition of the importance of advanced decontamination methods in government and critical infrastructure settings. The company's focus on expanding its corporate service contracts aligns with the trend of businesses seeking comprehensive solutions for infection prevention.

Comparison to Industry Standards

• While TOMI's gross margin of 60.2% is relatively strong, the decrease in revenue and increased net loss compared to the previous year are concerning.
• Companies like Steris and Ecolab, which are larger players in the infection prevention market, typically have more stable revenue streams and higher profitability.
• TOMI's reliance on a few key products and government contracts makes it more vulnerable to fluctuations in demand and project delays compared to more diversified competitors.
• The company's growth in iHP service revenue is a positive sign, but it needs to demonstrate consistent revenue growth and profitability to compete effectively with established industry leaders.

Stakeholder Impact

• Shareholders may be concerned about the decreased revenue and increased losses.
• Employees may be impacted by the company's performance and future growth plans.
• Customers may benefit from the company's continued innovation and expansion of services.
• Suppliers may be affected by the company's financial performance and purchasing decisions.

Next Steps

• The company will focus on executing its strategies to grow revenues and expand business development.
• The company will continue to develop government relationships.
• The company will install the new $600,000 CES system by the end of the third quarter of 2024.
• The company will await a decision on the $3,000,000 Department of Defense grant proposal.

Key Dates

Keywords

disinfection, decontamination, SteraMist, Binary Ionization Technology, iHP, CES, revenue, financial results, healthcare, pharmaceuticals, government contracts